Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
NewAmsterdam Pharma Company N.V. Warrant (NAMSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/29/2025: NAMSW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 33.03% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/29/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.03 | 52 Weeks Range 5.45 - 16.75 | Updated Date 05/17/2025 |
52 Weeks Range 5.45 - 16.75 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2314.47% |
Management Effectiveness
Return on Assets (TTM) -18.15% | Return on Equity (TTM) -31.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 54899238 |
Shares Outstanding - | Shares Floating 54899238 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NewAmsterdam Pharma Company N.V. Warrant
Company Overview
History and Background
NewAmsterdam Pharma Company N.V. Warrant is an entity associated with NewAmsterdam Pharma, a biopharmaceutical company focused on developing and commercializing novel treatments for respiratory and cardiovascular diseases. The company was founded with the goal of addressing unmet medical needs in these therapeutic areas. Specific founding year and detailed historical milestones for the warrant itself are not readily available as warrants are typically derivative instruments tied to the underlying company's existence and performance.
Core Business Areas
- Respiratory Diseases: Development and commercialization of therapeutics targeting respiratory conditions such as asthma, COPD, and pulmonary fibrosis.
- Cardiovascular Diseases: Focus on innovative treatments for various cardiovascular ailments.
Leadership and Structure
Information on the specific leadership team for the warrant entity is not typically disclosed separately. The leadership and structure would be that of the parent company, NewAmsterdam Pharma.
Top Products and Market Share
Key Offerings
- Product Name 1: NewAmsterdam Pharma is in the process of developing a pipeline of drug candidates. Specific product names and their market share data are not yet publicly available as the company is in its development phase. Competitors would vary depending on the specific therapeutic area and drug candidate.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and innovation-driven, with significant investment in research and development. The respiratory and cardiovascular disease markets are substantial, with a continuous demand for new and effective treatments due to aging populations and lifestyle-related health issues. Regulatory hurdles and patent cliffs are key factors influencing market dynamics.
Positioning
NewAmsterdam Pharma, and by extension its warrant, is positioned as a development-stage biopharmaceutical company seeking to carve out a niche in the respiratory and cardiovascular therapeutic areas by focusing on novel therapies. Its competitive advantage would stem from its R&D pipeline and the potential for its drug candidates to address unmet medical needs.
Total Addressable Market (TAM)
The Total Addressable Market for respiratory and cardiovascular drugs is in the hundreds of billions of dollars globally. NewAmsterdam Pharma's positioning within this TAM is currently aspirational, dependent on the successful development and commercialization of its pipeline products. As a development-stage company, its current market share is negligible, but its potential upside is tied to capturing a portion of this large market.
Upturn SWOT Analysis
Strengths
- Focus on significant unmet medical needs in respiratory and cardiovascular diseases.
- Potential for innovative drug candidates within its R&D pipeline.
- Experienced management team (assumed for a biopharma company of this nature).
Weaknesses
- Development-stage company with no approved products yet, leading to revenue generation challenges.
- High R&D costs and inherent risks associated with drug development.
- Reliance on future funding and successful clinical trials.
- Limited market share and brand recognition at this stage.
Opportunities
- Growing demand for advanced treatments for chronic respiratory and cardiovascular conditions.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Advancements in biotechnology and drug delivery systems.
- Acquisition targets for larger players in the pharmaceutical industry.
Threats
- Intense competition from established pharmaceutical companies with existing blockbuster drugs.
- Failure in clinical trials leading to significant financial losses and reputational damage.
- Stringent regulatory approval processes and potential delays.
- Patent expirations and generic competition for future products.
- Changes in healthcare policies and reimbursement rates.
Competitors and Market Share
Key Competitors
- Gilead Sciences (GILD)
- AbbVie Inc. (ABBV)
- Regeneron Pharmaceuticals, Inc. (REGN)
- AstraZeneca PLC (AZN)
- Pfizer Inc. (PFE)
Competitive Landscape
NewAmsterdam Pharma N.V. operates in highly competitive therapeutic areas with many established players. Its advantage lies in the potential for novel therapies that could offer significant improvements over existing treatments. However, it faces the challenge of a long and expensive drug development process, regulatory hurdles, and the need to differentiate its products in a crowded market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for NewAmsterdam Pharma N.V. would be measured by its progress in its R&D pipeline, securing funding, and expanding its scientific and operational capabilities. It is a relatively young company in its development cycle.
Future Projections: Future projections are heavily dependent on the success of its drug development programs. Analyst estimates, if available, would focus on projected timelines for clinical trial phases, potential market penetration of its lead candidates, and future revenue forecasts post-commercialization.
Recent Initiatives: Recent initiatives would likely involve progressing its lead drug candidates through clinical trials, potentially filing for regulatory approvals, and engaging in strategic partnerships or collaborations to advance its pipeline.
Summary
NewAmsterdam Pharma Company N.V. Warrant represents a speculative investment in a development-stage biopharmaceutical company. Its primary strength lies in its potential to develop innovative treatments for significant medical needs, while its major weakness is the inherent risk and uncertainty in drug development. The company needs to successfully navigate clinical trials and regulatory approvals to realize its market potential, while carefully managing its cash burn and fending off competition from established giants.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Financial news outlets
- Industry analysis reports
- General financial data providers
Disclaimers:
This JSON output is generated based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions. Data on market share for development-stage companies is often inferred or based on specific drug segments rather than the entire company.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewAmsterdam Pharma Company N.V. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-11-23 | CEO, President, Executive Board Member & Director Dr. Michael Harvey Davidson FACC, Facp., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 77 | |
Full time employees 77 | |||
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.